Intelligence · Clinical Pipeline
SANGAMO THERAPEUTICS Pipeline
All ClinicalTrials.gov programs at SANGAMO THERAPEUTICS — phase, modality, and trial IDs.
- Programs
- 7
Quick answer
SANGAMO THERAPEUTICS has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
CERE-110: Adeno-Associated Virus Delivery of NGF
SANGAMO THERAPEUTICS, INC
Alzheimer's Disease
1 trial -
CERE-120: AAV2-NTN
SANGAMO THERAPEUTICS, INC
Parkinson's Disease
1 trial -
SB-728-T
SANGAMO THERAPEUTICS, INC
HIV Infection
1 trial -
SB-728mR-HSPC Infusion 3 days following busulfan conditioning
SANGAMO THERAPEUTICS, INC
HIV
1 trial -
SB-FIX
SANGAMO THERAPEUTICS, INC
Hemophilia B
1 trial -
ZFN modified T cells
SANGAMO THERAPEUTICS, INC
HIV
1 trial -
hVEGF-A
SANGAMO THERAPEUTICS, INC
Diabetic Neuropathy
1 trial
Frequently asked questions
How many pipeline programs does SANGAMO THERAPEUTICS have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs